Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Single Shot Adductor Canal Block for ACL Reconstruction
NCT04101682Phase 1Terminated
- Sponsor
- Northwell Health
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bupivacaine in postoperative pain (2 arms), sponsored by Northwell Health. Primary endpoints: Pain at Rest at Day 14 and Worst Pain in the past 24 hours at Day 14. Started Sep 2020; status: terminated.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04101682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101682.